Table 3. Multivariate analysis for disease-free survival.
|
Disease-free survival in all patients |
||||
|---|---|---|---|---|
|
Multivariate analysis |
||||
| Variables | Category | P | HR | 95% CI |
| Age, years | <62 vs ⩾62 | 0.584 | 0.613 | 0.106–3.534 |
| Gender | Female vs male | 0.250 | 3.879 | 0.385–39.115 |
| pTNM stage | I vs II and III | 0.014 | 13.863 | 1.688–113.847 |
| WHO classification | GCLS vs non-GCLS | 0.695 | 0.551 | 0.028–10.859 |
| Lymphatic invasion | Negative vs positive | 0.026 | 0.139 | 0.024–0.788 |
| Venous invasion | Negative vs positive | 0.027 | 0.055 | 0.004–0.715 |
| Perineural invasion | Negative vs positive | 0.096 | 4.702 | 0.762–29.034 |
| Str-TILs | ⩾25 vs <25 | 0.647 | 1.982 | 0.106–36.975 |
| iTu-PD-L1 | Negative vs positive | 0.006 | 12.085 | 2.013–72.559 |
Abbreviations: CI=confidence interval; GCLS=gastric carcinoma with lymphoid stroma; R=hazard ratio; iTu=intratumoural; PD-L1=programmed cell death protein ligand-1; str=stromal; TILs=tumour-infiltrating lymphocytes; WHO = World Health Organization.